ACR Alpine Capital Research’s Elevance Health ELV Stock Holding History

ACR Alpine Capital Research’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$285M	Buy	+737,922	New	+$274M	4.05%	14

Other funds holding ELV

HGIM

High Ground Investment Management London, United Kingdom $1.14B AUM 29.32% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Focused Investors Los Angeles, California $2.96B AUM 15.6% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Canoe Financial Calgary, Alberta, Canada $8.07B AUM 25.47% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

MIHAS

Maj Invest Holding A/S Copenhagen K, Denmark $2.2B AUM 25.64% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

ACR Alpine Capital Research's ELV Position: Q2 2026 in Review

ACR Alpine Capital Research opened a new position in Elevance Health (ELV) in Q2 2026: 737,922 shares worth $285M. The stake represents 4.05% of the portfolio and ranks #14 among its holdings.

565 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

ACR Alpine Capital Research held 737,922 shares of Elevance Health worth $285M as of Q2 2026.
Elevance Health was a new ACR Alpine Capital Research position in Q2 2026.
Elevance Health made up 4.05% of ACR Alpine Capital Research's portfolio in Q2 2026, its #14 holding.
565 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on ACR Alpine Capital Research's 13F filing for Q2 2026, filed 29 Jul 2026.